SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gets approval to sell Truvada drug in India from DCGI

24 May 2016 Evaluate

Cipla has received regulatory approval in India from the Drug Controller General of India (DCGI) to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV. Truvada is priced at Rs 2,200 for a month. The Truvada has been in use in India for about eight years now, but only for the treatment of people with the HIV infection. The big difference now is that it is used to prevent infection in healthy people.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1231.60 -6.70 (-0.54%)
20-Apr-2026 14:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.75
Dr. Reddys Lab 1233.95
Cipla 1231.60
Zydus Lifesciences 938.70
Lupin 2328.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×